79 related articles for article (PubMed ID: 9652458)
1. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection.
Mutapi F; Ndhlovu PD; Hagan P; Spicer JT; Mduluza T; Turner CM; Chandiwana SK; Woolhouse ME
J Infect Dis; 1998 Jul; 178(1):289-93. PubMed ID: 9652458
[TBL] [Abstract][Full Text] [Related]
2. Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
Mitchell KM; Mutapi F; Mduluza T; Midzi N; Savill NJ; Woolhouse ME
PLoS Negl Trop Dis; 2014; 8(7):e3059. PubMed ID: 25079601
[TBL] [Abstract][Full Text] [Related]
3. Schistosoma haematobium infection levels determine the effect of praziquantel treatment on anti-schistosome and anti-mite antibodies.
Rujeni N; Nausch N; Midzi N; Mduluza T; Taylor DW; Mutapi F
Parasite Immunol; 2012 Jun; 34(6):330-40. PubMed ID: 22429049
[TBL] [Abstract][Full Text] [Related]
4. Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis.
Pearson MS; Tedla BA; Becker L; Nakajima R; Jasinskas A; Mduluza T; Mutapi F; Oeuvray C; Greco B; Sotillo J; Felgner PL; Loukas A
Front Immunol; 2021; 12():663041. PubMed ID: 34113343
[TBL] [Abstract][Full Text] [Related]
5. Schistosome infection intensity is inversely related to auto-reactive antibody levels.
Mutapi F; Imai N; Nausch N; Bourke CD; Rujeni N; Mitchell KM; Midzi N; Woolhouse ME; Maizels RM; Mduluza T
PLoS One; 2011 May; 6(5):e19149. PubMed ID: 21573157
[TBL] [Abstract][Full Text] [Related]
6. Age-related patterns in human myeloid dendritic cell populations in people exposed to Schistosoma haematobium infection.
Nausch N; Louis D; Lantz O; Peguillet I; Trottein F; Chen IY; Appleby LJ; Bourke CD; Midzi N; Mduluza T; Mutapi F
PLoS Negl Trop Dis; 2012; 6(9):e1824. PubMed ID: 23029585
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Differences in Host Response to
Dupnik KM; Reust MJ; Vick KM; Yao B; Miyaye D; Lyimo E; Mukerebe C; Mngara J; Kalluvya SE; de Dood CJ; Corstjens PLAM; van Dam GJ; Zhang T; Xiang J; Lee MH; Downs JA
Infect Immun; 2019 Jan; 87(1):. PubMed ID: 30323023
[TBL] [Abstract][Full Text] [Related]
8. Considering treatment of male genital schistosomiasis as a tool for future HIV prevention: a systematic review.
Stecher CW; Kallestrup P; Kjetland EF; Vennervald B; Petersen E
Int J Public Health; 2015 Nov; 60(7):839-48. PubMed ID: 26298443
[TBL] [Abstract][Full Text] [Related]
9. Group 2 innate lymphoid cell proportions are diminished in young helminth infected children and restored by curative anti-helminthic treatment.
Nausch N; Appleby LJ; Sparks AM; Midzi N; Mduluza T; Mutapi F
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003627. PubMed ID: 25799270
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of
Houmsou RS; Wama BE; Agere H; Uniga JA; Jerry TJ; Azuaga P; Amuta EU; Kela SL
Adv Lab Med; 2021 Mar; 2(1):71-86. PubMed ID: 37359201
[TBL] [Abstract][Full Text] [Related]
11. Praziquantel Treatment of
Nono JK; Mpotje T; Mosala P; Aziz NA; Musaigwa F; Hlaka L; Spangenberg T; Brombacher F
Front Immunol; 2021; 12():748387. PubMed ID: 34956183
[TBL] [Abstract][Full Text] [Related]
12. What is the impact of acquired immunity on the transmission of schistosomiasis and the efficacy of current and planned mass drug administration programmes?
Kura K; Hardwick RJ; Truscott JE; Anderson RM
PLoS Negl Trop Dis; 2021 Dec; 15(12):e0009946. PubMed ID: 34851952
[TBL] [Abstract][Full Text] [Related]
13. Associations of IL13 gene polymorphisms and immune factors with Schistosoma haematobium infection in schoolchildren in four schistosomiasis-endemic communities in Ghana.
Sarpong-Baidoo M; Ofori MF; Asuming-Brempong EK; Kyei-Baafour E; Idun BK; Owusu-Frimpong I; Amonoo NA; Quarshie QD; Tettevi EJ; Osei-Atweneboana MY
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009455. PubMed ID: 34185775
[TBL] [Abstract][Full Text] [Related]
14. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
[TBL] [Abstract][Full Text] [Related]
15. Current Understanding of Immunity Against Schistosomiasis: Impact on Vaccine and Drug Development.
Molehin AJ
Res Rep Trop Med; 2020; 11():119-128. PubMed ID: 33173371
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Risk Factors Associated with
Ndassi VD; Anchang-Kimbi JK; Sumbele IUN; Wepnje GB; Kimbi HK
J Parasitol Res; 2019; 2019():4397263. PubMed ID: 31354982
[TBL] [Abstract][Full Text] [Related]
17. Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity.
Chisango TJ; Ndlovu B; Vengesai A; Nhidza AF; Sibanda EP; Zhou D; Mutapi F; Mduluza T
BMC Infect Dis; 2019 Mar; 19(1):219. PubMed ID: 30832614
[TBL] [Abstract][Full Text] [Related]
18. Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents.
Ajibola O; Rowan AD; Ogedengbe CO; Mshelia MB; Cabral DJ; Eze AA; Obaro S; Belenky P
Sci Rep; 2019 Jan; 9(1):829. PubMed ID: 30696838
[TBL] [Abstract][Full Text] [Related]
19. Population level changes in schistosome-specific antibody levels following chemotherapy.
Fukushige M; Mutapi F; Woolhouse MEJ
Parasite Immunol; 2019 Jan; 41(1):e12604. PubMed ID: 30467873
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
